1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
62A39AFAEABE7029F00258CBD001B1551
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-maximizing-impact-infectious-disease-analytics-insights-teams-delivering-value-structure-branding-innovation?opendocument
18
19opendocument
2018.97.14.83
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Market Research, Analytics and Forecasting » Analytics

Maximizing the Impact of Infectious Disease Analytics and Insights Teams: Delivering Value through Structure, Branding, and Innovation

ID: 5886


Features:

16 Info Graphics

20 Data Graphics

320+ Metrics

11 Narratives


Pages/Slides: 45


Published: 2025


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Maximizing the Impact of Infectious Disease Analytics and Insights Teams: Delivering Value through Structure, Branding, and Innovation”

STUDY OVERVIEW

Infectious Disease is a fast-evolving therapeutic area, where sudden outbreaks, shifting resistance trends, and time-sensitive regulatory changes require proactive, data-driven decisions. Analytics & Insights (A&I) teams play a crucial role in driving such informed decisions, provided they are structured effectively and recognized as a strategic internal partner.

Best Practices, LLC conducted this benchmarking study to guide Infectious Disease A&I teams in building more agile structures, fostering client-centric service models, and reinforcing their organizational value through internal branding. This study examines the key capabilities and practices that enable these teams to thrive under pressure and remain adaptable in a constantly changing landscape.


KEY TOPICS

  • Key responsibilities and clients supported by Infectious Disease A&I teams
  • Valuable strategic practices, skill sets, and expertise areas
  • Internal branding programs
  • Common A&I pitfalls, challenges, and lessons
  • Innovative pilots, design thinking and patient-centric engagement

KEY METRICS

  • Time allocated by Infectious Disease A&I teams across key internal groups – Total benchmark class
  • Role of Infectious Disease A&I groups in fulfilling organizational capabilities
  • Strategic initiatives driven by Infectious Disease A&I teams use to drive stakeholder value
  • Soft skills and prior experience backgrounds valued in Infectious Disease A&I teams
  • Most critical technical skills for Infectious Disease A&I professionals
  • Top barriers to the future success of the Infectious Disease Analytics & Insights function
  • Internal branding campaign rollout to shape perception of the Infectious Disease A&I group
  • Key objectives behind internal branding in Infectious Disease Analytics & Insights functions
  • Design thinking adoption in infectious disease A&I innovation efforts
  • Direct patient engagement efforts to understand real-world infectious disease needs
  • Disease areas where patient engagement has driven impact – by therapeutic scope (primary care, specialty, rare)
  • Disease areas where patient engagement has driven impact – by drug type and route of administration

SAMPLE KEY FINDINGS

  • Top-Ranked Challenges: Infectious Disease A&I advisors say the biggest obstacle facing the group’s success is “achieving receptivity of insights by stakeholders”. Related challenges include: #2) cultivating right relationships, and #3) deriving actionable insights and recommendations.

METHODOLOGY

Best Practices, LLC engaged 10 Analytics & Insights leaders from 10 leading biopharma organizations specializing in infectious diseases. The study provides segmentation by company size (mid vs. large pharma) and incorporates in-depth interviews for richer qualitative context. Notably, more than 20% of benchmark participants hold director-level or higher roles.

Industries Profiled:
Biotech; Pharmaceutical; Research; Consulting; Health Care; Diagnostic


Companies Profiled:
Bio-Rad Laboratories Inc.; Biotest AG; CSL Seqirus; Janssen; Lonza Inc.; MEDiSTRAVA; Merck; Qiagen; Takeda Pharmaceuticals

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.